Cassava Sciences (SAVA) CEO Remi Barbier is 13 days away from a $3 million cash bonus, thanks to a well-timed change in the company’s executive compensation plan and a questionable reanalysis of an unsuccessful Alzheimer’s disease drug clinical trial.

Barbier has a reputation for profiting personally even while his company suffered multiple setbacks. This latest money grab is particularly shameless because it’s practically risk-free — for him.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Any chance you guys could start writing case studies like Harvard Business Review on these types of shenanigans in the biotech industry? It would really help investors steer clear of companies with this kind of CEO.

  • Nice piece on Cassava. Shows how criminal people can be and how naive investors are. Taints our entire industry.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy